Convalescent Plasma Therapy - Zurich Protocol (CPT-ZHP)
A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
The outbreak of a new highly contagious and life-threatening infective disease was first reported in China in December 2019. Regardless of the undertaken containing measures, its spreading could not be effectively stopped and currently we are confronting the pandemic diffusion of a newly identified Coronavirus (SARS-CoV-2) (1). This causes a systemic disease, known as (Coronavirus Disease-19) COVID-19, characterised by a broad spectrum of clinical manifestations, including ineffective hyper-inflammation and severe pneumonia, with provisional epidemiologic data indicating a mortality rate of 0.1-15% (2). Do to the lack of vaccination, specific anti-virus sera or monoclonal antibodies, the therapeutic efforts to limit COVID-19 mostly rely on the empirical use of anti-viral drugs. Therefore, being the option of an active immunisation not available and because of the controversial efficacy of the available anti-viral therapies (3), we suggest the option of a passive immunisation for those patients who are infected with the new coronavirus and present dyspnea or a poor prognosis. The use of convalescent plasma, i.e. plasma obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection, could provide a rapid protection, limiting the observed evolution of COVID-19 towards life-threating manifestations (7-9).
When carried on according to standardised measures, the transfusion of plasma is highly safe (10-11) and we assume that products containing anti- SARS-CoV- 2 antibodies will provide the recipients a passive immunity through different mechanisms, including viral neutralisation, antibody-dependent cellular cytotoxicity and/or phagocytosis.
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Zürich、瑞士、8091
- University Hospital Zurich
-
-
参与标准
资格标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
A) Proven Sars-CoV-2 by PCR and hospitalization for COVID-19 in combination with either (1) or (2):
Age ≥50
AND (at least one):
- Pre-existing cardiovascular disease
- Diabetic disease
- Immunodeficiency/immunosuppression
- Neoplastic disease
- COPD or chronic liver disease or chronic renal failure
- Age ≥18
AND (at least one):
- SpO2 ≤ 94% on room air or requiring supplemental oxygen at screening
- Typical changes on chest x-ray and/or lung-CT scan
- Immunosuppression or neoplastic disease
B) Informed Consent as documented by signature (Appendix Informed Consent Form) of the patient or, in case of inability, of the next relative/care-taking person. In the latter case, an independent doctor will also be involved and her/his signature will be required in order to enrol the patient.
Exclusion Criteria:
- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product (FFP)
- Known IgA deficiency
- Cytokine Release Syndrome grade ≥3 (see score)*
- ARDS
- Patients already hospitalized in intensive care unit and/or already receiving mechanical ventilation
- Known or suspected non-compliance, drug or alcohol abuse
- Previous enrolment into the current study
- Enrolment of the investigator, his/her family members, employees and other dependent persons
- Women who are pregnant or breast feeding
- Intention to become pregnant during the course of the study
- Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety of CPT applied to COVID-19 patients
大体时间:clinical observation up to 48 hours after the last dose of plasma
|
Absence of clinical signs of Transfusion Related Lung Inflammation (TRALI) and/or allergic reactions and/or Transfusion Associated Circulatory Overload (TACO)
|
clinical observation up to 48 hours after the last dose of plasma
|
|
Safety of CPT applied to COVID-19 patients
大体时间:1 week (laboratory monitoring up to 7 days after the last administration of plasma)
|
Absence of laboratory signs of haemolytic reactions
|
1 week (laboratory monitoring up to 7 days after the last administration of plasma)
|
|
Improvement of respiratory frequency
大体时间:3 weeks after the last administration of plasma
|
Respiratory frequency will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of O2-saturation
大体时间:3 weeks after the last administration of plasma
|
O2-Saturation will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of Inflammatory markers (C Reactive Protein, CRP)
大体时间:3 weeks after the last administration of plasma
|
CRP will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of Inflammatory markers (Ferritin)
大体时间:3 weeks after the last administration of plasma
|
Ferritin will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of Inflammatory markers (IL-6)
大体时间:3 weeks after the last administration of plasma
|
IL-6 will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of coagulation-markers (D-dimer)
大体时间:3 weeks after the last administration of plasma
|
D-Dimer will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of coagulation-markers (Fibrinogen)
大体时间:3 weeks after the last administration of plasma
|
Fibrinogen will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Improvement of coagulation-markers (LDH)
大体时间:3 weeks after the last administration of plasma
|
LDH will be measured at each study visit
|
3 weeks after the last administration of plasma
|
|
Prevention of ICU-admission
大体时间:3 weeks after the last administration of plasma
|
clinical conditions will be assessed throughout the study
|
3 weeks after the last administration of plasma
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Characterisation of virus reaction to plasma Therapy
大体时间:10 Weeks
|
Measurement of viral load after plasma therapy
|
10 Weeks
|
|
Characterisation of the dynamic of humoral response after therapy
大体时间:10 Weeks
|
Measurement of antibody-titres after plasma therapy
|
10 Weeks
|
|
Better characterize the the in-vivo anti-virus humoral response against SARS-CoV-2.
大体时间:10 Weeks
|
Performance of neutralisation assay after administration of plasma
|
10 Weeks
|
合作者和调查者
调查人员
调查人员
- 学习椅:Markus Manz, Professor、University of Zurich
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- 2020-00787
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.